Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
- Author
- HUGHES, Tim P1 ; KAEDA, Jaspal2 ; RADICH, Jerald P5 ; BRANFORD, Susan1 ; RUDZKI, Zbigniew1 ; HOCHHAUS, Andreas3 ; HENSLEY, Martee L4 ; GATHMANN, Insa4 ; BOLTON, Ann E4 ; VAN HOOMISSEN, Iris C4 ; GOLDMAN, John M2
[1] Institute of Medical and Veterinary Science, Adelaide, Australia
[2] Hammersmith Hospital, London, United Kingdom
[3] III, Medizinische Klinik, Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany
[4] Novartis Pharma, Basel, Switzerland
[5] Fred Hutchinson Cancer Research Center, Seattle, United States
International Randomised Study of Interferon versus STI571 (IRIS) Study Group, International - Source
The New England journal of medicine. 2003, Vol 349, Num 15, pp 1423-1432, 10 p ; ref : 40 ref
- CODEN
- NEJMAG
- ISSN
- 0028-4793
- Scientific domain
- General medicine general surgery
- Publisher
- Massachusetts Medical Society, Boston, MA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Chimiothérapie Chronique Cytarabine Efficacité traitement Homme Interféron alpha Leucémie myéloïde Pyrimidine nucléoside Traitement associé Traitement Imatinib Cytokine Hémopathie maligne Myéloprolifératif syndrome
- Keyword (en)
- Chemotherapy Chronic Cytarabine Treatment efficiency Human Alpha interferon Chronic myelocytic leukemia Pyrimidine nucleoside Combined treatment Treatment Cytokine Malignant hemopathy Myeloproliferative syndrome
- Keyword (es)
- Quimioterapia Crónico Citarabina Eficacia tratamiento Hombre Interferón alfa Leucemia mieloidea Pirimidina nucleósido Tratamiento asociado Tratamiento Citoquina Hemopatía maligna Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15180130
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1056/NEJMoa030513 
https://dx.doi.org/10.1056/NEJMoa030513
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:3:\"349\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1423\";s:8:\"\u0000*\u0000epage\";s:4:\"1432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HUGHES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Tim P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"KAEDA, Jaspal\";i:1;s:16:\"RADICH, Jerald P\";i:2;s:15:\"BRANFORD, Susan\";i:3;s:16:\"RUDZKI, Zbigniew\";i:4;s:17:\"HOCHHAUS, Andreas\";i:5;s:17:\"HENSLEY, Martee L\";i:6;s:14:\"GATHMANN, Insa\";i:7;s:13:\"BOLTON, Ann E\";i:8;s:21:\"VAN HOOMISSEN, Iris C\";i:9;s:15:\"GOLDMAN, John M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:3:\"349\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1423\";s:8:\"\u0000*\u0000epage\";s:4:\"1432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HUGHES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Tim P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"KAEDA, Jaspal\";i:1;s:16:\"RADICH, Jerald P\";i:2;s:15:\"BRANFORD, Susan\";i:3;s:16:\"RUDZKI, Zbigniew\";i:4;s:17:\"HOCHHAUS, Andreas\";i:5;s:17:\"HENSLEY, Martee L\";i:6;s:14:\"GATHMANN, Insa\";i:7;s:13:\"BOLTON, Ann E\";i:8;s:21:\"VAN HOOMISSEN, Iris C\";i:9;s:15:\"GOLDMAN, John M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:3:\"349\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1423\";s:8:\"\u0000*\u0000epage\";s:4:\"1432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HUGHES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Tim P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"KAEDA, Jaspal\";i:1;s:16:\"RADICH, Jerald P\";i:2;s:15:\"BRANFORD, Susan\";i:3;s:16:\"RUDZKI, Zbigniew\";i:4;s:17:\"HOCHHAUS, Andreas\";i:5;s:17:\"HENSLEY, Martee L\";i:6;s:14:\"GATHMANN, Insa\";i:7;s:13:\"BOLTON, Ann E\";i:8;s:21:\"VAN HOOMISSEN, Iris C\";i:9;s:15:\"GOLDMAN, John M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:3:\"349\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1423\";s:8:\"\u0000*\u0000epage\";s:4:\"1432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HUGHES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Tim P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"KAEDA, Jaspal\";i:1;s:16:\"RADICH, Jerald P\";i:2;s:15:\"BRANFORD, Susan\";i:3;s:16:\"RUDZKI, Zbigniew\";i:4;s:17:\"HOCHHAUS, Andreas\";i:5;s:17:\"HENSLEY, Martee L\";i:6;s:14:\"GATHMANN, Insa\";i:7;s:13:\"BOLTON, Ann E\";i:8;s:21:\"VAN HOOMISSEN, Iris C\";i:9;s:15:\"GOLDMAN, John M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1056\/NEJMoa030513\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:3:\"349\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1423\";s:8:\"\u0000*\u0000epage\";s:4:\"1432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HUGHES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Tim P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"KAEDA, Jaspal\";i:1;s:16:\"RADICH, Jerald P\";i:2;s:15:\"BRANFORD, Susan\";i:3;s:16:\"RUDZKI, Zbigniew\";i:4;s:17:\"HOCHHAUS, Andreas\";i:5;s:17:\"HENSLEY, Martee L\";i:6;s:14:\"GATHMANN, Insa\";i:7;s:13:\"BOLTON, Ann E\";i:8;s:21:\"VAN HOOMISSEN, Iris C\";i:9;s:15:\"GOLDMAN, John M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia\";s:8:\"\u0000*\u0000place\";s:10:\"Boston, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
